Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. MSFT
10. IBM

Go back to Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
(NASDAQ: NTLA) Delayed: 15.75 --0 (-0%)
Previous Close $15.75    52 Week High $30.40 
Open $15.75    52 Week Low $11.86 
Day High $15.75    P/E N/A 
Day Low $15.75    EPS $0.00 
Volume 30,788